Listed

Plexus Corp: Form 10-Q for the period ended Dec 30, 2023

Filed with the SEC on Feb 2, 2024 and accepted by EDGAR at Feb 2, 2024, 13:08 ET.

Share

Management's discussion and analysis

As filed, 34,561 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

"SAFE HARBOR" CAUTIONARY STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995:

The statements contained in this Form 10-Q that are guidance or which are not historical facts (such as statements in the future tense and statements including believe, expect, intend, plan, anticipate, goal, target and similar terms and concepts), including all discussions of periods which are not yet completed, are forward-looking statements that involve risks and uncertainties. These risks and uncertainties include the effect of inflationary pressures on our costs of production, profitability, and on the economic outlook of our markets; the effects of shortages and delays in obtaining components as a result of economic cycles, natural disasters or otherwise; the risk of customer delays, changes, cancellations or forecast inaccuracies in both ongoing and new programs; the effects of our Xiamen, China subsidiary being placed on the Bureau of Industry and Security's Unverified list; the ability to realize anticipated savings from restructuring or similar actions, as well as the adequacy of related charges as compared to actual expenses; the lack of visibility of future orders, particularly in view of changing economic conditions; the economic performance of the industries, sectors and customers we serve; the outcome of litigation and regulatory investigations and proceedings, including the results of any challenges with regard to such outcomes; the effects of tariffs, trade disputes, trade agreements and other trade protection measures; the effects of the volume of revenue from certain sectors or programs on our margins in particular periods; our ability to secure new customers, maintain our current customer base and deliver product on a timely basis; the risks of concentration of work for certain customers; the particular risks relative to new or recent customers, programs or services, which risks include customer and other delays, start-up costs, potential inability to execute, the establishment of appropriate terms of agreements, and the lack of a track record of order volume and timing; the effects of start-up costs of new programs and facilities or the costs associated with the closure or consolidation of facilities; possible unexpected costs and operating disruption in transitioning programs, including transitions between Company facilities; the risk that new program wins and/or customer demand may not result in the expected revenue or profitability; the fact that customer orders may not lead to long-term relationships; our ability to manage successfully and execute a complex business model characterized by high product mix and demanding quality, regulatory, and other requirements; the risks associated with excess and obsolete inventory, including the risk that inventory purchased on behalf of our customers may not be consumed or otherwise paid for by the customer, resulting in an inventory write-off; risks related to information technology systems and data security; increasing regulatory and compliance requirements; any tax law changes and related foreign jurisdiction tax developments; current or potential future barriers to the repatriation of funds that are currently held outside of the United States as a result of actions taken by other countries or otherwise; the potential effects of jurisdictional results on our taxes, tax rates, and our ability to use deferred tax assets and net operating losses; the weakness of areas of the global economy; the effect of changes in the pricing and margins of products; raw materials and component cost fluctuations; the potential effect of fluctuations in the value of the currencies in which we transact business; the effects of changes in economic conditions, political conditions and tax matters in the United States and in the other countries in which we do business; the potential effect of other world or local events or other events outside our control (such as the conflict between Russia and Ukraine, conflict in the Middle East, escalating tensions between China and Taiwan or China and the United States, changes in energy prices, terrorism, global health epidemics and weather events); the impact of increased competition; an inability to successfully manage human capital; changes in financial accounting standards; and other risks detailed herein and in our other Securities and Exchange Commission filings, particularly in Risk Factors contained in our fiscal 2023 Form 10-K.

OVERVIEW

Plexus Corp. and its subsidiaries (together "Plexus," the "Company", "our", or "we") participate in the Electronic Manufacturing Services ("EMS") industry. Since 1979, we have been partnering with companies to create the products that build a better world. We are a global leader with a team of over 20,000 individuals who are dedicated to providing Design and Development, Supply Chain Solutions, New Product Introduction, Manufacturing and Sustaining Services. We specialize in serving customers in industries with highly complex products and demanding regulatory environments. We deliver customer service excellence to leading global companies in the Healthcare/Life Sciences, Industrial and Aerospace/Defense market sectors by providing innovative, comprehensive solutions throughout the product's lifecycle. We provide these innovative solutions to customers in the Americas ("AMER"), Asia-Pacific ("APAC") and Europe, Middle East and Africa ("EMEA") regions.

The following Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") is intended to provide an analysis of both short-term results and future prospects from management’s perspective, including an assessment of the financial condition and results of operations, events and uncertainties that are not indicative of future operations and any other financial or statistical data that we believe will enhance the understanding of our company’s financial condition, cash flows and other changes in financial condition and results of operations

The following information should be read in conjunction with our condensed consolidated financial statements included herein and "Risk Factors" included in Part II, Item 1A included herein as well as Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2023, and our "Safe Harbor" Cautionary Statement included above.

Market Pressures Update

We have experienced an inability to procure certain components on a timely basis due to global supply chain constraints. These constraints have impacted our ability to meet customer demand and may inhibit our ability to capture the demand from our customers. The extended lead-times have required us to make additional investments in inventory to satisfy customer demand.

During the first quarter of fiscal 2024, we have experienced market-driven inventory corrections at our customers inventory corrections at the customers and incrementally weaker demand from the Healthcare/Lifesciences and Industrial market sectors creating inefficiencies within our operations. We expect the market-driven inventory corrections at the customers and weaker demand in certain sectors to be a near-term challenge that will lessen later in fiscal 2024. However, if market softness continues for extended periods, this would impact our operating results in future periods.

A global minimum tax has been, or is anticipated to be, implemented in many of the countries in which we operate. We anticipate this will materially and unfavorably impact our existing tax holidays and effective tax rate beginning in our fiscal 2025. We will continue to monitor these developments as each jurisdiction incorporates such changes into tax laws.

We believe our balance sheet is positioned to support the potential future challenges presented by the macro-economic pressures we are facing. As of the first quarter of fiscal 2024, cash and cash equivalents and restricted cash were $232 million, while debt, finance lease obligations and other financing were $443 million. Borrowings under our Credit Facility as of December 30, 2023 were $243.0 million, leaving $257 million of our revolving commitment of $500 million available for use as well as the ability to expand our revolving commitment to $750 million upon mutual agreement with the bank. Interest expense could increase above current levels due to increased borrowing under our Credit Facility associated with working capital investments along with the impact of rising interest rates. Refer to Note 3, "Debt, Finance Lease and Other Financing Obligations," in Notes to Condensed Consolidated Financial Statements and "Management’s Discussion and Analysis Liquidity and Capital Resources" in Part I, Item 2 for further information.

RESULTS OF OPERATIONS

Consolidated Performance Summary. The following table presents selected consolidated financial data (dollars in millions, except per share data):

Three Months Ended December 30, 2023 December 31, 2022
Net sales $982.6 $1,093.9
Cost of sales 894.5 992.7
Gross profit 88.1 101.2
Gross margin 9.0% 9.3%
Operating income 45.2 57.3
Operating margin 4.6% 5.2%
Other expense 10.3 7.9
Income tax expense 5.6 7.2
Net income 29.2 42.2
Diluted earnings per share $1.04 $1.49
Return on invested capital* 10.3% 13.8%
Economic return* 2.1% 4.8%
*Non-GAAP metric; refer to "Return on Invested Capital ("ROIC") and economic return" below and Exhibit 99.1 for more information.

Net sales. For the three months ended December 30, 2023, net sales decreased $111.3 million, or 10.2%, as compared to the three months ended December 31, 2022.

Net sales are analyzed by management by geographic segment, which reflects our reportable segments, and by market sector. Management measures operational performance and allocates resources on a geographic segment basis. Our global business development strategy is based on our targeted market sectors.

A discussion of net sales by reportable segment is presented below (in millions):

Net sales: Three Months Ended December 30, 2023 December 31, 2022
AMER $333.7 $389.7
APAC 552.5 641.9
EMEA 121.9 89.4
Elimination of inter-segment sales (25.5) (27.1)
Total net sales $982.6 $1,093.9

AMER. Net sales for the three months ended December 30, 2023 in the AMER segment decreased $56.0 million, or 14.4%, as compared to the three months ended December 31, 2022. The decrease in net sales was driven by overall net decreased customer end-market demand inclusive of market-driven inventory corrections at the customers as well as reductions in inflated component pricing. The decrease was partially offset by an increase of $8.7 million due to production ramps for new customers.

APAC. Net sales for the three months ended December 30, 2023 in the APAC segment decreased $89.4 million, or 13.9%, as compared to the three months ended December 31, 2022. The decrease in net sales was driven by overall net decreased customer end-market demand inclusive of market-driven inventory corrections at the customers as well as reductions in inflated component pricing, partially offset by a partial easing of supply chain constraints. The decrease was further offset by a $12.3 million increase due to production ramps of new products for existing customers.

EMEA. Net sales for the three months ended December 30, 2023 in the EMEA segment increased $32.5 million, or 36.4%, as compared to the three months ended December 31, 2022. The increase in net sales was driven by a $15.6 million increase due to production ramps for a new customer and overall net increased customer end-market demand. The increase was further driven by a $5.2 million increase in production ramps of new products for existing customers, partially offset by reductions in inflated component pricing.

Our net sales by market sector for the indicated fiscal period were as follows (in millions):

Net sales: Three Months Ended December 30, 2023 December 31, 2022
Healthcare/Life Sciences $380.9 $487.9
Industrial 434.6 472.1
Aerospace/Defense 167.1 133.9
Total net sales $982.6 $1,093.9

Healthcare/Life Sciences. Net sales for the three months ended December 30, 2023 in the Healthcare/Life Sciences sector decreased $107.0 million, or 21.9%, as compared to the three months ended December 31, 2022. The decrease in net sales was driven by overall net decreased customer end-market demand inclusive of market-driven inventory corrections at the customers as well as a reduction in inflated component pricing. The decrease was partially offset by an increase of $9.1 million due to production ramps of new products for existing customers.

Industrial. Net sales for the three months ended December 30, 2023 in the Industrial sector decreased $37.5 million, or 7.9%, as compared to the three months ended December 31, 2022. The decrease in net sales was driven by overall net decreased customer end-market demand inclusive of market-driven inventory corrections at the customers as well as reductions in inflated component pricing. The decrease was partially offset by an increase of $20.7 million due to production ramps for new customers.

Aerospace/Defense. Net sales for the three months ended December 30, 2023 in the Aerospace/Defense sector increased $33.2 million, or 24.8%, as compared to the three months ended December 31, 2022. The increase was driven by overall net increased customer end-market demand and an $8.0 million increase due to production ramps of new products for existing customers. The increase was partially offset by a reduction in inflated component pricing.

Cost of sales. Cost of sales for the three months ended December 30, 2023 decreased $98.2 million, or 9.9%, as compared to the three months ended December 31, 2022. Cost of sales is comprised primarily of material and component costs, labor costs and overhead. For the three months ended December 30, 2023 and December 31, 2022, approximately 89% to 91% of the total cost of sales was variable in nature and fluctuated with sales volumes. Approximately 87% to 88% of these costs were related to material and component costs.

As compared to the three months ended December 31, 2022, the decrease in cost of sales for the three months ended December 30, 2023 was primarily driven by the decrease in net sales and a positive shift in customer mix, partially offset by an increase in fixed costs.

Gross profit. Gross profit for the three months ended December 30, 2023 decreased $13.1 million, or 12.9%, as compared to the three months ended December 31, 2022. Gross margin of 9.0% for the three months ended December 30, 2023 decreased 30 basis points compared to the three months ended December 31, 2022. The primary drivers of the decrease in gross profit and gross margin as compared to the three months ended December 31, 2022 were the decrease in net sales and an increase in fixed costs to support new customer program ramps, partially offset by a positive shift in customer mix.

Operating income. Operating income for the three months ended December 30, 2023 decreased $12.1 million, or 21.1%, as compared to the three months ended December 31, 2022. Operating margin of 4.6% for the three months ended December 30, 2023 decreased 60 basis points compared to the three months ended December 31, 2022. The primary driver of the decrease in operating income and operating margin for the three months ended December 30, 2023 was the result of the decrease in gross margin partially offset by a $0.9 million decrease in selling and administrative expenses ("S&A"). The decrease in S&A was primarily due to a decrease in incentive compensation costs.

A discussion of operating income by reportable segment for the indicated fiscal period(in millions):

Operating income: Three Months Ended December 30, 2023 December 31, 2022
AMER $8.7 $17.4
APAC 71.4 78.4
EMEA (0.2) (0.6)
Corporate and other costs (34.7) (37.9)
Total operating income $45.2 $57.3

AMER. Operating income decreased $8.7 million for the three months ended December 30, 2023 as compared to the three months ended December 31, 2022 primarily as a result of a decrease in net sales, partially offset by a positive shift in customer mix.

APAC. Operating income decreased $7.0 million for the three months ended December 30, 2023 as compared to the three months ended December 31, 2022 primarily as a result of a decrease in net sales, partially offset by a positive shift in customer mix and a decrease in S&A.

EMEA. Operating income increased $0.4 million for the three months ended December 30, 2023 as compared to the three months ended December 31, 2022 primarily as a result of an increase in net sales, partially offset by increased fixed costs.

Other expense. Other expense for the three months ended December 30, 2023 increased $2.4 million as compared to the three months ended December 31, 2022. The increase in other expense for the three months ended December 30, 2023 was primarily driven by a decrease in other miscellaneous income of $0.9 million, an increase in interest expense of $0.7 million due to a higher average interest rate and the higher average daily borrowing levels and an increase in factoring fees of $0.6 million.

Income taxes. Income tax expense for the three months ended December 30, 2023 was $5.6 million compared to $7.2 million for the three months ended December 31, 2022. The decrease is primarily due to a decrease in pre-tax book income.

Our annual effective tax rate varies from the U.S. statutory rate of 21.0% primarily due to the geographic distribution of worldwide earnings as well as a tax holiday granted to a subsidiary located in the APAC segment where we derive a significant portion of our earnings. Our effective tax rate may also be impacted by disputes with taxing authorities, tax planning activities, adjustments to uncertain tax positions and changes in valuation allowances.

The annual effective tax rate for fiscal 2024 is expected to be approximately 15.0% to 17.0% assuming no changes to tax laws.

Net Income. Net income for the three months ended December 30, 2023 decreased $13.0 million, or 30.8%, for the three months ended December 31, 2022 to $29.2 million. Net income decreased primarily as a result of the decrease in operating income and the increase in other expense, partially offset by the decrease in tax expense as previously discussed.

Diluted earnings per share. Diluted earnings per share decreased to $1.04 for the three months ended December 30, 2023 from $1.49 for the three months ended December 31, 2022 primarily as a result of decreased net income due to the factors discussed above, partially offset by a reduction in diluted shares outstanding.

Return on Invested Capital ("ROIC") and economic return. We use a financial model that is aligned with our business strategy and includes an ROIC goal of 15% which would exceed our weighted average cost of capital ("WACC") by more than 500 basis points and represent positive economic return. Economic return is the amount our ROIC exceeds our WACC.

Non-GAAP financial measures, including ROIC and economic return, are used for internal management goals and decision making because such measures provide management and investors additional insight into financial performance. In particular, we provide ROIC and economic return because we believe they offer insight into the metrics that are driving management decisions. We view ROIC and economic return as important measures in evaluating the efficiency and effectiveness of our long-term capital investments. We also use ROIC as a performance criteria in determining certain elements of compensation as well as economic return performance.

We define ROIC as tax-effected operating income before restructuring and other special items divided by average invested capital over a rolling two-quarter period for the first period. Invested capital is defined as equity plus debt and operating lease liabilities, less cash and cash equivalents. Other companies may not define or calculate ROIC in the same way. ROIC and other non-GAAP financial measures should be considered in addition to, not as a substitute for, measures of our financial performance prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP").

We review our internal calculation of WACC annually. Our WACC is 8.2% for fiscal 2024 and 9.0% for fiscal 2023. By exercising discipline to generate ROIC in excess of our WACC, our goal is to create value for our shareholders. For the three months ended December 30, 2023, ROIC of 10.3% reflects an economic return of 2.1%, based on our WACC of 8.2%, and for the three months ended December 31, 2022, ROIC of 13.8% reflects an economic return of 4.8%, based on our weighted average cost of capital of 9.0%.

For a reconciliation of ROIC, economic return and adjusted operating income (tax-effected) to our financial statements that were prepared using U.S. GAAP, see Exhibit 99.1 to this quarterly report on Form 10-Q, which exhibit is incorporated herein by reference.

Refer to the table below, which includes the calculation of ROIC and economic return for the indicated fiscal period (dollars in millions):

Three Months Ended December 30, 2023 December 31, 2022
Adjusted operating income (tax-effected) $151.7 $192.7
Average invested capital 1,479.6 1,392.0
After-tax ROIC 10.3% 13.8%
WACC 8.2% 9.0%
Economic return 2.1% 4.8%

LIQUIDITY AND CAPITAL RESOURCES

Cash and cash equivalents and restricted cash were $232.4 million as of December 30, 2023 as compared to $256.7 million as of September 30, 2023.

As of December 30, 2023, 90% of our cash and cash equivalents balance was held outside of the U.S. by our foreign subsidiaries. Currently, we believe that our cash balance, together with cash available under our Credit Facility, will be sufficient to meet our liquidity needs and potential share repurchases for the next twelve months and the foreseeable future.

Our future cash flows from operating activities will be reduced by $42.0 million due to cash payments for U.S. federal taxes on the deemed repatriation of undistributed foreign earnings that are payable over an eight year period that began in fiscal 2019 with the first payment. The table below provides the expected timing of these future cash outflows, in accordance with the following installment schedule for the remaining three years (in millions):

Remaining 2024 $10.6
2025 14.1
2026 17.3
Total $42.0

Cash Flows. The following table provides a summary of cash flows (in millions):

Three Months Ended December 30, 2023 December 31, 2022
Cash flows used in operating activities $(3.0) $(48.8)
Cash flows used in investing activities (28.6) (21.6)
Cash flows provided by financing activities 5.8 39.4
Effect of exchange rate changes on cash and cash equivalents 1.6 3.4
Net decrease in cash and cash equivalents and restricted cash $(24.2) $(27.6)

23

Operating Activities. Cash flows used in operating activities were $3.0 million for the three months ended December 30, 2023, as compared to cash flows used in operating activities of $48.8 million for the three months ended December 31, 2022. The decrease was primarily due to cash flow improvements (reductions) of:

  • $(13.0) million decrease in net income.
  • $58.7 million in accounts payables cash flows primarily driven by the timing of materials procurement and payments to suppliers.
  • $26.4 million in inventory cash flows driven by inventory levels increasing at a slower rate in the three months ended December 30, 2023 compared to the three months ended December 31, 2022 due to fewer program ramps requiring upfront inventory procurement.
  • $(28.2) million in advanced payments from customers cash flows driven by a larger decrease in advanced payments in the three months ended December 30, 2023 compared to the three months ended December 31, 2022.
  • $(9.0) million in contract assets cash flows, driven by decreases in advanced payments received from customers who recognize revenue over time.

The following table provides a summary of cash cycle days for the periods indicated (in days):

Three Months Ended December 30, 2023 December 31, 2022
Days in accounts receivable 61 61
Days in contract assets 12 10
Days in inventory 161 151
Days in accounts payable (66) (69)
Days in advanced payments (1) (73) (70)
Annualized cash cycle 95 83
(1) Includes a reclassification in the presentation of advanced payments from customers reflected in prior period amounts.As of December 31, 2022, the impact of this reclassification was an increase in the Company's days in advanced payments and a reduction in annualized cash cycle by 23 days.

We calculate days in accounts receivable and contract assets as each balance sheet item for the respective quarter divided by annualized sales for the respective quarter by day. We calculate days in inventory, accounts payable and advanced payments as each balance sheet line item for the respective quarter divided by annualized cost of sales for the respective quarter by day. We calculate annualized cash cycle as the sum of days in accounts receivable, days in contract assets and days in inventory, less days in accounts payable and days in advanced payments.

As of December 30, 2023, annualized cash cycle days increased twelve days compared to December 31, 2022 due to the following:

Days in accounts receivable for the three months ended December 30, 2023 remained flat compared to the three months ended December 31, 2022.

Days in contract assets for the three months ended December 30, 2023 increased two days compared to the three months ended December 31, 2022. The increase is primarily attributable to a decrease in advanced payments from customers with arrangements requiring revenue to be recognized over time as products are produced.

Days in inventory for the three months ended December 30, 2023 increased ten days compared to the three months ended December 31, 2022. The increase is primarily due to lower sales in the three months ended December 30, 2023 compared to the prior year, partially offset by lower inventory.

Days in accounts payable for the three months ended December 30, 2023 decreased three days compared to the three months ended December 31, 2022. The decrease is primarily attributable to timing of materials procurement and payments to suppliers.

Days in advanced payments for the three months ended December 30, 2023 increased three days compared to the three months ended December 31, 2022. The increase was primarily attributable to lower sales in the three months ended December 30, 2023 compared to the prior year, partially offset by a decrease in advanced payments received from customers in line with lower inventory balances.

Free Cash Flow. We define free cash flow ("FCF"), a non-GAAP financial measure, as cash flow generated or used in operations less capital expenditures. FCF was $(31.7) million for the three months ended December 30, 2023 compared to $(71.9) million for the three months ended December 31, 2022, an improvement of $40.2 million. The improvement in FCF was primarily due to lower working capital investments in inventory to support our customers and increased accounts payable due to timing of payments.

Non-GAAP financial measures, including FCF, are used for internal management assessments because such measures provide additional insight to investors into ongoing financial performance. In particular, we provide FCF because we believe it offers insight into the metrics that are driving management decisions. We view FCF as an important financial metric as it demonstrates our ability to generate cash and can allow us to pursue opportunities that enhance shareholder value. FCF is a non-GAAP financial measure that should be considered in addition to, not as a substitute for, measures of our financial performance prepared in accordance with GAAP.

A reconciliation of FCF to our financial statements that were prepared using GAAP as follows (in millions):

Three Months Ended December 30, 2023 December 31, 2022
Cash flows used in by operating activities $(3.0) $(48.8)
Payments for property, plant and equipment (28.7) (23.1)
Free cash flow $(31.7) $(71.9)

Investing Activities. Cash flows used in investing activities were $28.6 million for the three months ended December 30, 2023 compared to $21.6 million for the three months ended December 31, 2022. The increase in cash used in investing activities was due to a $5.6 million increase in capital expenditures.

We estimate capital expenditures for fiscal 2024 will be approximately $100.0 million to $120.0 million to support new program ramps and replace older equipment.

Financing Activities. Cash flows provided by financing activities were $5.8 million for the three months ended December 30, 2023 compared to cash flows provided by financing activities of $39.4 million for the three months ended December 31, 2022. The decrease was primarily attributable to net borrowings on the credit facility for the three months ended December 30, 2023 of $10.0 million compared to net borrowings on the credit facility for the three months ended December 31, 2022 of $57.0 million, as well as a $11.5 million reduction in repurchases of our common stock.

On August 18, 2022, the Board of Directors approved a share repurchase program under which we are authorized to repurchase up to $50.0 million of its common stock (the "2023 Program"). The 2023 Program became effective immediately and has no expiration. During the three months ended December 30, 2023 we purchased no shares under this program. During the three months ended December 31, 2022, we purchased 115,723 shares under this program for $11.5 million at an average price of $99.12 per share. As of December 30, 2023, $5.7 million of authority remained under the 2023 Program. All shares repurchased under the aforementioned program were recorded as treasury stock.

On January 16, 2024, we announced an additional $50.0 million in share repurchase authority (the "2024 Program") that authorizes us to repurchase our common stock. There is now a total of $55.7 million in repurchase authority under the combined 2023 and 2024 Programs. The 2024 Program will commence upon completion of the 2023 Program.

We have Master Accounts Receivable Purchase Agreements with MUFG Bank, New York Branch (formerly known as The Bank of Tokyo-Mitsubishi UFJ, Ltd.) (the "MUFG RPA"), HSBC Bank (China) Company Limited, Xiamen branch (the "HSBC RPA") and other unaffiliated financial institutions, under which we may elect to sell receivables, at a discount. These facilities are uncommitted facilities. The maximum facility amount under the MUFG RPA as of December 30, 2023 is $340.0 million. The maximum facility amount under the HSBC RPA as of December 30, 2023 is $70.0 million. The MUFG RPA will be automatically extended each year unless any party gives no less than 10 days prior notice that the agreement should not be extended. The terms of the HSBC RPA are generally consistent with the terms of the MUFG RPA previously discussed.

We sold $223.6 million and $185.6 million of trade accounts receivable under these programs during the three months ended December 30, 2023 and December 31, 2022, respectively, in exchange for cash proceeds of $221.0 million and $183.6 million, respectively. As of December 30, 2023 and December 31, 2022, $226.9 million and $196.8 million, respectively, of accounts receivables sold under trade accounts receivable programs and subject to servicing by us remained outstanding and had not yet been collected by MUFG Bank or HSBC Bank.

In all cases, the sale discount was recorded within "Miscellaneous, net" in the Condensed Consolidated Statements of Comprehensive Income in the period of the sale. For further information regarding the receivable sale programs, see Note 13, "Trade Accounts Receivable Sale Programs," in Notes to Condensed Consolidated Financial Statements.

Based on current expectations, we believe that our projected cash flows provided by operations, available cash and cash equivalents, potential borrowings under the Credit Facility and our leasing capabilities should be sufficient to meet our working capital and fixed capital requirements, as well as execution upon our share repurchase authorizations as management deems appropriate, for the next twelve months. We believe our balance sheet is positioned to support the potential future challenges presented by macroeconomic factors including increased working capital requirements associated with longer lead-times for components, increased component and labor costs, and operating inefficiencies due to supply chain constraints. As of the end of the first quarter of fiscal 2024, cash and cash equivalents and restricted cash were $232 million, while debt, finance lease and other financing obligations were $443 million. If our future financing needs increase, then we may need to arrange additional debt or equity financing. Accordingly, we evaluate and consider from time to time various financing alternatives to supplement our financial resources. However, we cannot be assured that we will be able to make any such arrangements on acceptable terms or at all.

DISCLOSURE ABOUT CRITICAL ACCOUNTING ESTIMATES

Our critical accounting policies are disclosed in our 2023 Annual Report on Form 10-K. During the first quarter of fiscal 2024, there were no material changes.

NEW ACCOUNTING PRONOUNCEMENTS

See Note 1, "Recently Adopted Accounting Pronouncements" and "Recently Issued Accounting Pronouncements Not Yet Adopted," in Notes to Condensed Consolidated Financial Statements regarding recent accounting pronouncements.

Market risk

As filed, 4,436 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

There were no material changes in our exposure to market risk from changes in foreign exchange and interest rates from those disclosed in our 2023 Annual Report on Form 10-K.

Foreign Currency Risk

Our international operations create potential foreign exchange risk. Our policy is to selectively hedge our foreign currency denominated transactions in a manner that partially offsets the effects of changes in foreign currency exchange rates. We typically use foreign currency contracts to hedge only those currency exposures associated with certain assets and liabilities denominated in non-functional currencies. Corresponding gains and losses on the underlying transaction generally offset the gains and losses on these foreign currency hedges. We cannot predict changes in currency rates, nor the degree to which we will be able to manage the impacts of currency exchange rate changes. Such changes could have a material effect on our business, results of operations and financial condition.

Our percentages of transactions denominated in currencies other than the U.S. dollar for the indicated periods were as follows:

Three Months Ended December 30, 2023 December 31, 2022
Net Sales 10% 7%
Total Costs 18% 15%

We have evaluated the potential foreign currency exchange rate risk on transactions denominated in currencies other than the U.S. dollar for the periods presented above. Based on our overall currency exposure, as of December 30, 2023, a 10.0% change in the value of the U.S. dollar relative to our other transactional currencies would not have a material effect on our financial position, results of operations, or cash flows.

Interest Rate Risk

We have financial instruments, including cash equivalents and debt, which are sensitive to changes in interest rates. The primary objective of our investment activities is to preserve principal, while maximizing yields without significantly increasing market risk. To achieve this, we limit the amount of principal exposure to any one issuer.

As of December 30, 2023, we were exposed to interest rate risk associated with our Credit Facility. Borrowings under the Credit Facility bear interest, at the Company's option, at (a)(1) for borrowings denominated in U.S. dollars, the Term Secured Overnight Financing Rate ("SOFR"), (2) for borrowings denominated in pounds sterling, the Daily Simple Risk-Free Rate, plus, in each case of (a)(1) and (2), 10 basis points, (b) for borrowings denominated in euros, the EURIBOR Rate plus a statutory reserve rate, or (c) an Alternate Base Rate equal to the highest of (i) 100 basis points per annum, (ii) the prime rate last quoted by The Wall Street Journal (or, if not quoted, as otherwise provided in the Credit Facility), (iii) the greater of the federal funds effective rate and the overnight bank funding rate in effect on such day plus, in each case, 50 basis points per annum (or, if neither are available, as otherwise provided in the Credit Facility), and (iv) Term SOFR for a one month interest period on such day plus 110 basis points, plus, in each case of (a), (b), and (c), an applicable interest rate margin based on the Company's then current consolidated total indebtedness (minus certain unrestricted cash and cash equivalents in an amount not to exceed $100 million) to consolidated EBITDA. As of December 30, 2023, the borrowing rate under the Credit Facility was SOFR plus 1.10%. Borrowings under the 2018 NPA are based on a fixed interest rate, thus mitigating much of our interest rate risk. We were also exposed to interest rate risk on our accounts receivables sales programs. The Master Accounts Receivable Purchase Agreements with MUFG Bank, New York Branch (the "MUFG RPA") is subject to an applicable cost of funds based on an applicable margin defined in the agreement with respect to receivables owed by each approved obligor and the applicable SOFR for a period equal to the discount period applicable to such receivable determined as of two business days prior to the applicable purchase date of such receivable with respect to the currency the receivable is denominated in. Other trade receivable sales programs are subject to similar terms. Based on our overall interest rate exposure, as of December 30, 2023, a 10.0% change in interest rates would not have a material effect on our financial position, results of operations, or cash flows.

Controls and procedures

As filed, 1,647 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Disclosure Controls and Procedures

The Company maintains disclosure controls and procedures designed to ensure that the information the Company must disclose in its filings with the Securities and Exchange Commission ("SEC") is recorded, processed, summarized and reported on a timely basis. The Company’s Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO") have reviewed and evaluated, with the participation of the Company’s management, the Company’s disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act") as of the end of the period covered by this report. Based on such evaluation, the CEO and CFO have concluded that, as of the Evaluation Date, the Company’s disclosure controls and procedures are effective, at the reasonable assurance level, (a) in recording, processing, summarizing and reporting, on a timely basis, information required to be disclosed by the Company in the reports the Company files or submits under the Exchange Act, and (b) in assuring that information is accumulated and communicated to the Company’s management, including the CEO and CFO, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

During the first quarter of fiscal 2024, there have been no changes in the Company’s internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

Risk factors

As filed, 406 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

In addition to the risks and uncertainties discussed herein, particularly those discussed in the “Safe Harbor” Cautionary Statement and "Management’s Discussion and Analysis of Financial Condition and Results of Operations" in Part I, Item 2, see the risk factors set forth in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2023 that have had no material changes.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2023-12-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2023-10-01 to 2023-12-30$1.01bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2023-10-01 to 2023-12-30$894.5mus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2023-10-01 to 2023-12-30$88.1mus-gaap:GrossProfit
Selling, general and administrative3 months2023-10-01 to 2023-12-30$43.0mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2023-10-01 to 2023-12-30$45.2mus-gaap:OperatingIncomeLoss
Interest expense3 months2023-10-01 to 2023-12-30$7.6mus-gaap:InterestExpense
Income tax3 months2023-10-01 to 2023-12-30$5.6mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2023-10-01 to 2023-12-30$29.2mus-gaap:NetIncomeLoss
Diluted EPS3 months2023-10-01 to 2023-12-30$1.04us-gaap:EarningsPerShareDiluted
Basic EPS3 months2023-10-01 to 2023-12-30$1.06us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2023-10-01 to 2023-12-3028,013,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow3 months2023-10-01 to 2023-12-30−$3.0mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2023-10-01 to 2023-12-30$28.7mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Share repurchases3 months2023-10-01 to 2023-12-30$0us-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2023-12-30$232.0mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2023-12-30$2.65bnus-gaap:AssetsCurrent
Total assetsAt period end2023-12-30$3.30bnus-gaap:Assets
Current liabilitiesAt period end2023-12-30$1.74bnus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2023-12-30$2.04bnus-gaap:Liabilities
Shareholders' equityAt period end2023-12-30$1.27bnus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0000785786-24-000017. Last ingested by Listed: Oct 24, 2026, 14:56 ET. Listed shows no prices and gives no investment advice.